Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.55 USD

76.55
859,950

+1.47 (1.96%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $76.58 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why Haemonetics (HAE) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Haemonetics (HAE) Hits 52-Week High: What's Aiding the Stock?

Investors are optimistic about Haemonetics' (HAE) potential in its Plasma franchise.

Indrajit Bandyopadhyay headshot

4 Stocks to Watch Amid Recovering Medical Products Industry

Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised to gain from the favorable factors.

3 Reasons Why Haemonetics (HAE) Is a Great Growth Stock

Haemonetics (HAE) possesses solid growth attributes, which could help it handily outperform the market.

Here's Why Haemonetics (HAE) is a Great Momentum Stock to Buy

Does Haemonetics (HAE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up

Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.

Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of 9.43% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates

Insulet (PODD) delivered earnings and revenue surprises of -128.57% and 2.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Surpasses Q2 Earnings and Revenue Estimates

Zimmer (ZBH) delivered earnings and revenue surprises of 11.66% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises

Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).

Here's Why You Should Retain Haemonetics (HAE) Stock For Now

Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.

Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Haemonetics (HAE) Gains on Procedure Recovery Amid Cost Woes

A strong procedure recovery in the hospital business, the resilience of blood donors in blood centers, and rollouts of Persona technology and NexSys aid Haemonetics (HAE).

Here's Why Investors Should Retain Haemonetics (HAE) For Now

Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.

Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up

Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of 8.33% and 2.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

3 Medical Product Stocks Set to Beat on Earnings This Season

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.

Clover Health (CLOV) to Report Q1 Earnings: What's in Store?

Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.

Viemed Healthcare, Inc. (VMD) Lags Q1 Earnings Estimates

Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of -33.33% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?

Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.

AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?

AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.

McKesson (MCK) to Report Q4 Earnings: What's in the Cards?

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?

PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at the Diagnostics segment.